Neurocrine Biosciences (NBIX) Capital Expenditures (QoQ) (2010 - 2026)
Powered by 
Analysis
Neurocrine Biosciences (NBIX) Capital Expenditures (QoQ) (2010 - 2026) Analysis & Trends
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Johnson & Johnson | 646.71 Bn | 625.95 Bn | 17.26 Bn |
| 2 | AbbVie | 442.22 Bn | 435.65 Bn | 12.70 Bn |
| 3 | Merck | 366.92 Bn | 359.78 Bn | 12.21 Bn |
| 4 | Novartis Ag | 266.90 Bn | 259.21 Bn | 11.24 Bn |
| 5 | Pfizer | 159.20 Bn | 147.50 Bn | 10.94 Bn |
| 6 | Sanofi | 52.44 Bn | 45.06 Bn | 10.79 Bn |
| 7 | Revolution Medicines | 44.11 Bn | 44.11 Bn | - |
| 8 | Incyte | 25.38 Bn | 20.85 Bn | 1.57 Bn |
| 9 | United Therapeutics | 21.50 Bn | 18.84 Bn | 683.80 Mn |
| 10 | Neurocrine Biosciences | 15.58 Bn | 15.19 Bn | 935.80 Mn |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | -14.29% |
| Mar 31, 2026 | 479.17% |
| Dec 31, 2025 | -118.18% |
| Sep 30, 2025 | 5.60% |
| Jun 30, 2025 | 16.82% |
| Mar 31, 2025 | 46.58% |
| Dec 31, 2024 | -9.88% |
| Sep 30, 2024 | -30.17% |
| Jun 30, 2024 | 3.57% |
| Mar 31, 2024 | 107.41% |
| Dec 31, 2023 | -28.95% |
| Sep 30, 2023 | 11.76% |
| Jun 30, 2023 | -20.00% |
| Mar 31, 2023 | 372.22% |
| Dec 31, 2022 | 205.88% |
| Sep 30, 2022 | -119.32% |
| Jun 30, 2022 | 15.79% |
| Mar 31, 2022 | -14.61% |
| Dec 31, 2021 | 56.14% |
| Sep 30, 2021 | 32.56% |